P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

類似資料

• Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
  著者:: Lee YP, 等
  出版事項: (2021-05-01)
• Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma
  著者:: Lorenzo Falchi, 等
  出版事項: (2026-12-01)
• An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
  著者:: Yilmaz U, 等
  出版事項: (2021-09-01)
• The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context
  著者:: Radhakrishnan Ramchandren, 等
  出版事項: (2023-02-01)
• The AUGMENT study: Lenalidomide in indolent lymphoma . . . balance the imbalance!
  著者:: Reyad Dada
  出版事項: (2020-01-01)